El-Karaksy Hanaa M, El-Koofy Nehal, Mohsen Nabil, Helmy Heba, Nabil Nevian, El-Shabrawi Mortada
Department of Pediatrics, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
J Pediatr Gastroenterol Nutr. 2015 Jan;60(1):105-9. doi: 10.1097/MPG.0000000000000548.
Extrahepatic portal vein obstruction (EHPVO) is an important cause of portal hypertension in children. The aim of this study was to describe the clinical presentation, possible risk factors, upper gastrointestinal endoscopic findings, and treatment modalities of children with EHPVO.
After ethical approval of our study protocol by our institution review board, we analyzed available data from medical records of patients with EHPVO presenting to the Pediatric Hepatology Unit, Cairo University Pediatric Hospital, Egypt, for a period of 15 years from January 1996 to December 2010.
The study included 169 patients. Their ages at presentation ranged from 1 month to 12 years (median 2.5 years, interquartile range 5); 101 were boys. Hematemesis was a presenting symptom in 58%, splenomegaly was present in 87%, esophageal varices were present in 94%, and fundal varices were present in 23%. Possible risk factors, in the form of umbilical catheterization, umbilical sepsis, and exchange transfusion, were elicited in 18%. Propranolol was associated with reduction in bleeding episodes (P < 0.001), but was associated with increased chest symptoms (P < 0.01). Both injection sclerotherapy and band ligation were effective in the management of bleeding varices and for primary and secondary prophylaxis; however, injection sclerotherapy was associated with the development of secondary gastric varices (P = 0.03).
This large study of children with EHPVO demonstrates the efficacy of propranolol in the reduction of gastrointestinal bleeding in children with EHPVO. Both injection sclerotherapy and band ligation were effective in the management of esophageal varices, although the former was associated with the development of secondary gastric varices. Randomized clinical trials to choose the best modalities for the management of portal hypertension in children are still lacking.
肝外门静脉阻塞(EHPVO)是儿童门静脉高压的重要病因。本研究旨在描述EHPVO患儿的临床表现、可能的危险因素、上消化道内镜检查结果及治疗方式。
在我们的研究方案获得机构审查委员会的伦理批准后,我们分析了1996年1月至2010年12月期间在埃及开罗大学儿童医院儿科肝病科就诊的EHPVO患者病历中的可用数据,为期15年。
该研究纳入了169例患者。他们就诊时的年龄范围为1个月至12岁(中位数2.5岁,四分位间距5);其中101例为男孩。呕血是58%患者的首发症状,脾肿大见于87%的患者,食管静脉曲张见于94%的患者,胃底静脉曲张见于23%的患者。18%的患者存在可能的危险因素,表现为脐静脉插管、脐部感染和换血。普萘洛尔与出血发作次数减少相关(P<0.001),但与胸部症状增加相关(P<0.01)。注射硬化疗法和套扎术在治疗静脉曲张出血及一级和二级预防方面均有效;然而,注射硬化疗法与继发性胃静脉曲张的发生相关(P=0.03)。
这项针对EHPVO患儿的大型研究表明,普萘洛尔在减少EHPVO患儿胃肠道出血方面具有疗效。注射硬化疗法和套扎术在食管静脉曲张的治疗中均有效,尽管前者与继发性胃静脉曲张的发生相关。目前仍缺乏选择儿童门静脉高压最佳治疗方式的随机临床试验。